Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Debate

Exclusive and adjuvant radiotherapy in breast cancer patients with synchronous metastases

Authors: Romuald Le Scodan, David Ali, Denise Stevens

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Data from the Surveillance, Epidemiology, and End Results program and the European Concerted Action on survival and Care of Cancer Patients (EUROCARE) project indicate that about 6% of women newly diagnosed with breast cancer have stage IV disease, representing about 12 600 new cases per year in the United States in 2005. Historically, local therapy of the primary tumor in this setting has been aimed solely at symptom palliation. However, several studies suggest that surgical excision of the primary tumor can prolong these patients' survival.

Discussion

Exclusive locoregional radiotherapy is an alternative form of locoregional treatment in this setting and may represent an effective alternative to surgery in this setting. Here we discuss current issues regarding exclusive and adjuvant locoregional radiotherapy in breast cancer patients with synchronous metastases.

Summary

Several studies suggest that surgery or exclusive irradiation of the primary tumor is associated with better survival in breast cancer patients with synchronous metastases and that exclusive locoregional radiotherapy may represent an effective alternative to surgery in this setting. Results of well-designed prospective studies are needed to re-evaluate treatment of the primary breast tumor in patients with metastases at diagnosis, and to identify those patients who are most likely to benefit.
Literature
1.
Sant M: Differences in stage and therapy for breast cancer across Europe. Int J Cancer. 2001, 93: 894-901. 10.1002/ijc.1408.CrossRefPubMed
2.
3.
4.
Bernard-Marty C, Cardoso F, Piccart MJ: Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist. 2004, 9: 617-632. 10.1634/theoncologist.9-6-617.CrossRefPubMed
5.
Hortobagyi GN: Treatment of breast cancer. N Engl J Med. 1998, 339: 974-984. 10.1056/NEJM199810013391407.CrossRefPubMed
6.
Babiera GV, Rao R, Feng L, et al: Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006, 13: 776-782. 10.1245/ASO.2006.03.033.CrossRefPubMed
7.
Bafford AC, Burstein HJ, Barkley CR, et al: Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009, 115: 7-12. 10.1007/s10549-008-0101-7.CrossRefPubMed
8.
Blanchard DK, Shetty PB, Hilsenbeck SG, et al: Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008, 247 (5): 732-738. 10.1097/SLA.0b013e3181656d32.CrossRefPubMed
9.
Cady B, Nathan NR, Michaelson JS, et al: Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol. 2008, 15: 3384-3395. 10.1245/s10434-008-0085-x.CrossRefPubMed
10.
Fields RC, Jeffe DB, Trinkaus K, et al: Surgical Resection of the Primary Tumor is Associated with Increased Long-Term Survival in Patients with Stage IV Breast Cancer after Controlling for Site of Metastasis. Ann Surg Oncol. 2007, 14: 3345-3351. 10.1245/s10434-007-9527-0.CrossRefPubMed
11.
Gnerlich J, Jeffe DB, Deshpande AD, et al: Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol. 2007, 14: 2187-2194. 10.1245/s10434-007-9438-0.CrossRefPubMed
12.
Hazard HW, Gorla SR, Kim J, Scholtens D: Surgical resection of the primary tumor in stage IV breast cancer and survival. Cancer. 2008, 113: 2011-19. 10.1002/cncr.23870.CrossRefPubMed
13.
Khan SA, Stewart AK, Morrow M: Does aggressive local therapy improve survival in metastatic breast cancer?. Surgery. 2002, 132: 620-626. 10.1067/msy.2002.127544.CrossRefPubMed
14.
Le Scodan R, Stevens D, Brain E, et al: Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol. 2009, 27: 1375-1381. 10.1200/JCO.2008.19.5396.CrossRefPubMed
15.
Rao R, Feng L, Kuerer HM, et al: Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol. 2008, 15: 1696-1702. 10.1245/s10434-008-9830-4.CrossRefPubMed
16.
Rapiti E, Verkooijen HM, Vlastos G, et al: Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006, 24: 2743-2749. 10.1200/JCO.2005.04.2226.CrossRefPubMed
17.
Ruiterkamp J, Ernst MF, van de Poll-Franse LV, et al: Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol. 2009, 35 (11): 1146-51.CrossRefPubMed
18.
Shien T, Kinoshita T, Shimizu C, et al: Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep. 2009, 21: 827-832.PubMed
19.
Leung AM, Vu HN, Nguyen KA, et al: Effects of Surgical Excision on Survival of Patients with Stage IV Breast Cancer. J Surg Res. 2010, 161 (1): 83-8. 10.1016/j.jss.2008.12.030.CrossRefPubMed
20.
Bourgier C, Khodari W, Vataire AL, et al: Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease. Radiother Oncol. 2010,
21.
Flanigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001, 345: 1655-1659. 10.1056/NEJMoa003013.CrossRefPubMed
22.
Mickisch GH, Garin A, van Poppel H, et al: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001, 358: 966-970. 10.1016/S0140-6736(01)06103-7.CrossRefPubMed
23.
Hallissey MT, Allum WH, Roginski C, Fielding JW: Palliative surgery for gastric cancer. Cancer. 1988, 62: 440-444. 10.1002/1097-0142(19880715)62:2<440::AID-CNCR2820620232>3.0.CO;2-N.CrossRefPubMed
24.
Essner R, Lee JH, Wanek LA, et al: Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004, 139: 961-966. 10.1001/archsurg.139.9.961.CrossRefPubMed
25.
Rosen SA, Buell JF, Yoshida A, et al: Initial presentation with stage IV colorectal cancer: how aggressive should we be?. Arch Surg. 2000, 135: 530-534. 10.1001/archsurg.135.5.530.CrossRefPubMed
26.
Tanaka K, Shimada H, Matsuo K, et al: Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery. 2004, 136: 650-659. 10.1016/j.surg.2004.02.012.CrossRefPubMed
27.
Dauplat J, Le Bouedec G, Pomel C, Scherer C: Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol. 2000, 19: 42-48. 10.1002/1098-2388(200007/08)19:1<42::AID-SSU7>3.0.CO;2-M.CrossRefPubMed
28.
Fehm T, Sagalowsky A, Clifford E, et al: Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002, 8: 2073-2084.PubMed
29.
Falkson G, Gelman R, Falkson CI, et al: Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol. 1991, 9: 2153-2161.PubMed
30.
Hortobagyi GN, Smith TL, Legha SS, et al: Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983, 1: 776-786.PubMed
31.
Nash CH, Jones SE, Moon TE, et al: Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer. 1980, 46: 2380-2388. 10.1002/1097-0142(19801201)46:11<2380::AID-CNCR2820461113>3.0.CO;2-M.CrossRefPubMed
32.
Vincent MD, Powles TJ, Skeet R, et al: An analysis of possible prognostic features of long term and short term survivors of metastatic breast cancer. Eur J Cancer Clin Oncol. 1986, 22: 1059-1065. 10.1016/0277-5379(86)90006-4.CrossRefPubMed
33.
Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004, 351: 781-791. 10.1056/NEJMoa040766.CrossRefPubMed
34.
Cristofanilli M, Hayes DF, Budd GT, et al: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005, 23: 1420-1430. 10.1200/JCO.2005.08.140.CrossRefPubMed
35.
Caras I, Grigorescu A, Stavaru C, et al: Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother. 2004, 53: 1146-1152. 10.1007/s00262-004-0556-2.CrossRefPubMed
36.
Danna EA, Sinha P, Gilbert M, et al: Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004, 64: 2205-2211. 10.1158/0008-5472.CAN-03-2646.CrossRefPubMed
37.
Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999, 353: 1641-1648. 10.1016/S0140-6736(98)09201-0.CrossRefPubMed
38.
Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997, 337: 949-55. 10.1056/NEJM199710023371401.CrossRefPubMed
39.
Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997, 337: 956-962. 10.1056/NEJM199710023371402.CrossRefPubMed
40.
Clarke M, Collins R, Darby S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 366: 2087-2106.CrossRefPubMed
41.
Arriagada R, Rutqvist LE, Mattsson A, et al: Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol. 1995, 13: 2869-2878.PubMed
42.
Coffey JC, Wang JH, Smith MJ, et al: Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 2003, 4: 760-768. 10.1016/S1470-2045(03)01282-8.CrossRefPubMed
43.
Demicheli R, Retsky MW, Hrushesky WJ, et al: The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008, 19: 1821-1828. 10.1093/annonc/mdn386.CrossRefPubMed
44.
Retsky M, Demicheli R, Hrushesky W: Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat. 2001, 65: 217-224. 10.1023/A:1010626302152.CrossRefPubMed
45.
Retsky M, Bonadonna G, Demicheli R, et al: Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res. 2004, 6: R372-R374. 10.1186/bcr804.CrossRefPubMedPubMedCentral
46.
Dubray B, Mazeron JJ, Simon JM, et al: Time factors in breast carcinoma: influence of delay between external irradiation and brachytherapy. Radiother Oncol. 1992, 25: 267-272. 10.1016/0167-8140(92)90246-Q.CrossRefPubMed
47.
Mazeron JJ, Simon JM, Crook J, et al: Influence of dose rate on local control of breast carcinoma treated by external beam irradiation plus iridium 192 implant. Int J Radiat Oncol Biol Phys. 1991, 21: 1173-1177. 10.1016/0360-3016(91)90273-7.CrossRefPubMed
48.
Fourquet A, Campana F, Mosseri V, et al: Iridium-192 versus cobalt-60 boost in 3-7 cm breast cancer treated by irradiation alone: final results of a randomized trial. Radiother Oncol. 1995, 34: 114-120. 10.1016/0167-8140(94)01492-L.CrossRefPubMed
49.
Dubois JB, Salomon A, Gary-Bobo J, et al: Exclusive radical radiation therapy in breast carcinoma. Radiother Oncol. 1991, 20: 24-29. 10.1016/0167-8140(91)90108-S.CrossRefPubMed
50.
Van Limbergen E, Van der SE, Van den BW, et al: Local control of operable breast cancer after radiotherapy alone. Eur J Cancer. 1990, 26: 674-679. 10.1016/0277-5379(90)90115-A.CrossRefPubMed
51.
Harris JR, Sawicka J, Gelman R, Hellman S: Management of locally advanced carcinoma of the breast by primary radiation therapy. Int J Radiat Oncol Biol Phys. 1983, 9: 345-349.CrossRefPubMed
52.
Sheldon T, Hayes DF, Cady B, et al: Primary radiation therapy for locally advanced breast cancer. Cancer. 1987, 60: 1219-1225. 10.1002/1097-0142(19870915)60:6<1219::AID-CNCR2820600610>3.0.CO;2-2.CrossRefPubMed
53.
Spanos WJ, Montague ED, Fletcher GH: Late complications of radiation only for advanced breast cancer. Int J Radiat Oncol Biol Phys. 1980, 6: 1473-1476.CrossRefPubMed
54.
Courdi Adel , Ortholan C, Hannoun-Lévi JM, et al: Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients. Radiother Oncol. 2006, 79: 156-61. 10.1016/j.radonc.2006.04.005.CrossRefPubMed
55.
Pierquin B, Huart J, Raynal M, et al: Conservative treatment for breast cancer: long-term results (15 years). Radiother Oncol. 1991, 20: 16-23. 10.1016/0167-8140(91)90107-R.CrossRefPubMed
56.
Whelan TJ, Kim DH, Sussman J: Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol. 2008, 18: 257-264. 10.1016/j.semradonc.2008.04.008.CrossRefPubMed
57.
Whelan TJ, Pignol JP, Levine MN, et al: Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010, 362: 513-520. 10.1056/NEJMoa0906260.CrossRefPubMed
58.
59.
Soran A, Ozbas S, Kelsey SF, Gulluoglu BM: Randomiezd trial comparing locoregional resection of primary tumor with no surgery in stage IV breast cancer at the presentation (protocol MF07-01): a study of Turkish Federation of the National Societies for breast diseases. Breast J. 2009, 15: 399-403. 10.1111/j.1524-4741.2009.00744.x.CrossRefPubMed
60.
61.
Parmar V, Hawaldar RW, Pandey N, et al: Surgical removal of primary tumor in women with metastatic breast cancer--Is it really justified?. ASCO breast cancer symposium. 2009, abstract 323
Metadata
Title
Exclusive and adjuvant radiotherapy in breast cancer patients with synchronous metastases
Authors
Romuald Le Scodan
David Ali
Denise Stevens
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-630

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

STAMP alters the growth of transformed and ovarian cancer cells

Research article

PGF2α-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer

Research article

A novel spliced fusion of MLL with CT45A2in a pediatric biphenotypic acute leukemia

Study protocol

Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma

Research article

Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death

Research article

Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits